Ireland's Theravance Biopharma Q2 revenue rises 11% but misses estimates

Theravance Biopharma

10/08/2026 13:42

Overview
Ireland-based specialty pharma's Q2 revenue rose 11% yr/yr but missed analyst expectations
Adjusted net income for Q2 beat analyst estimates
Company expects Zymeworks acquisition to close in 2H 2026, pending shareholder approval

Outlook
Theravance expects Zymeworks acquisition to close in second half of 2026
Company expects full run-rate cost savings of $70 mln to materialize in 2H 2026
Theravance expects to achieve $100 mln TRELEGY milestone payment in 2026 if sales threshold met

Result Drivers
YUPELRI SALES - Collaboration revenue rose 11% yr/yr, driven by continued net sales growth and improved operating leverage from YUPELRI
COST REDUCTION - Operating expenses fell 35% yr/yr due to organizational restructuring and cost reduction initiatives
R&D AND SG&A CUTS - Lower R&D and SG&A expenses resulted from restructuring and wind-down of the CYPRESS clinical trial

Company press release: ID:nPn2yPZ3fa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$20.73 mln
$21.60 mln (6 Analysts)
Q2 Loss Per Share
 
$0.11
 
Q2 Adjusted Net Income
Beat
$9.47 mln
$3.06 mln (3 Analysts)
Q2 Net Loss
 
$5.90 mln
 
Q2 Operating Income
 
-$8.28 mln
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Theravance Biopharma, Inc. is $17.00, about 0.4% above its August 7 closing price of $16.93
The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 11 three months ago

Reuters Recommended Reads
Aug 10 - Tonix Q2 revenue rises sharply on TONMYA launch
Aug 10 - Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio
Aug 10 - Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)